New Drug Approvals
Follow New Drug Approvals on WordPress.com

FLAGS AND HITS

Flag Counter
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO

Archives

Categories

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Researchgate

Anthony Melvin Crasto Dr.

  Join me on Facebook FACEBOOK   ...................................................................Join me on twitter Follow amcrasto on Twitter     ..................................................................Join me on google plus Googleplus

MYSELF

DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 36Yrs Exp. in the feld of Organic Chemistry,Working for AFRICURE PHARMA as ADVISOR earlier with GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, NO ADVERTISEMENTS , ACADEMIC , NON COMMERCIAL SITE, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, ........amcrasto@gmail.com..........+91 9323115463, Skype amcrasto64 View Anthony Melvin Crasto Ph.D's profile on LinkedIn Anthony Melvin Crasto Dr.

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.7K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Recent Posts

Venglustat, Ibiglustat


Venglustat, Ibiglustat

CAS 1401090-53-6

C20H24FN3O2S, 389.5 g/mol

CAS 1629063-78-0, Ibiglustat L-malate, Venglustat malate, C24H30FN3O7S, 523.6 g/mol

Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate

[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate

To treat the neurological symptoms of Type 3 Gaucher disease

Venglustat, sold under the brand name Infilbray, is a medication used for the treatment of Gaucher disease.[1] It is a glucosylceramide synthase inhibitor.[1] It is used as the salt venglustat malate.[1] It is given by mouth.[1]

The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]

Venglustat was approved for medical use in the United States in November 2026.[2]

Medical uses

Venglustat indicated for the treatment of neurological manifestations of type 3 Gaucher disease in people weighing at least 15 kg (33 lb).[1]

Venglustat crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.[2]

Type 3 Gaucher disease is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids, due to a deficient or malfunctioning enzyme.[2]

Adverse effects

The most common side effects of venglustat include gastrointestinal symptoms as well as adverse effects on mood.[2]

Serious psychiatric risks, including suicidal ideation and behavior, have been reported.[2] Potential risks identified from animal studies include potential clouding of vision in younger people and adverse effects on fetal development when it is taken during pregnancy.[2]

History

The US Food and Drug Administration approved venglustat supported by data from a randomized, double-blind, multi-center clinical study enrolling 43 participants aged 12 years and older with type 3 Gaucher disease who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization.[2] Participants received either venglustat orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks.[2] Treatment effectiveness was evaluated using two assessments that capture the neurological symptoms central to daily life in participants with type 3 Gaucher disease, including those related to ataxia (loss of muscle control and coordination) and cognitive function.[2] At Week 52, participants treated with venglustat demonstrated improvement on a measure that combined both assessments compared to those taking enzyme replacement therapy for the treatment of non-neurologic manifestations of type 3 Gaucher disease.[2]

Society and culture

Venglustat was approved for medical use in the United States in November 2026.[3]

The US Food and Drug Administration (FDA) granted the application for venglustat, breakthrough therapy, rare pediatric disease, fast track, orphan drug, and priority review designations.[2][3] The FDA granted the approval of Infilbray to Genzyme Corporation.[2]

Names

Venglustat is the international nonproprietary name.[4]

Venglustat is sold under the brand name Infilbray.[2][3]

SYN

SYN

WO2020/163244, 2020,

Organic Process Research and Development, 2015, vol. 19, V 5, PG 576 – 581

Journal of Medicinal Chemistry, 2023, vol. 66, V 2, PG1601 – 1615

PAT

WO2012129084 – GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012129084&_cid=P12-MWR8EI-85348-1

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

References

  1. “Infilbray FDA label” (PDF). products.sanofi.us.
  2. “FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease” (Press release). FDA. 18 November 2026. Retrieved 19 November 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. “Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease”. Sanofi (Press release). 18 November 2026. Retrieved 19 November 2026.
  4. World Health Organization (2016). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76”. WHO Drug Information. 30 (3). hdl:10665/331020.

Further reading

  • Bhattiprolu M, Kappler M, Han TU, Henderson M, Serlin Y, Sidransky E (May 2026). “Pharmacotherapies for Gaucher disease: what’s new on the horizon?”. Expert Opinion on Pharmacotherapy. 27 (7): 585–597. doi:10.1080/14656566.2026.2667325. PMID 42153355.
Clinical data
Trade namesInfilbray
AHFS/Drugs.comInfilbray
License dataUS DailyMed: Venglustat
Routes of
administration
By mouth
Drug classGlucosylceramide synthase inhibitor
ATC codeNone
Legal status
Legal statusUS: ℞-only[1]
Identifiers
IUPAC name
CAS Number1401090-53-61629063-78-0
PubChem CID6019924260199241
IUPHAR/BPS11550
DrugBankDB14966
ChemSpider34989426
UNIIBLP1XA3FZA94855LQZ8D
KEGGD11633D11634
ChEBICHEBI:757083
ChEMBLChEMBL4297611ChEMBL4594270
PDB ligandKYF (PDBe, RCSB PDB)
Chemical and physical data
FormulaC20H24FN3O2S
Molar mass389.49 g·mol−1
3D model (JSmol)Interactive imageInteractive image
SMILES
InChI

PAT

////////venglustat, ANAX LABS, Infilbray, APPROVALS 2026, FDA 2026, Genz-682452, GZ/SAR402671, BLP1XA3FZA, SAR-402671, SAR 402671, Genz-682452-AA, BLP1XA3FZA, GZ402671, WHO 10063, Ibiglustat L-malate, Venglustat malate

#venglustat, #ANAX LABS, #Infilbray, #APPROVALS 2026, #FDA 2026, #Genz-682452, #GZ/SAR402671, #BLP1XA3FZA, #SAR-402671, #SAR 402671, #Genz-682452-AA, #BLP1XA3FZA, #GZ402671, #WHO 10063, #Ibiglustat L-malate, #Venglustat malate

Adrabetadex


Adrabetadex

CAS128446-35-5

MF C54H94O38, MW
1351.3 g/mol

APPROVALS 2026, FDA 2026, Lembaz, 8W6Q67R6NX, KLEPTOSE HPB, VT-270, VTS270, VTS-270, Niemann–Pick disease type C,

2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2)

HYDROXYPROPYL BETADEX (0.6 HYDROXYPROPYL RESIDUES PER GLUCOSE)

(1S,3R,5R,6S,8R,10R,11S,13S,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,47R,48S,49R)-5,20,30,35-tetrakis(hydroxymethyl)-49-(2-hydroxypropoxy)-10,15,25-tris(2-hydroxypropoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,47,48-dodecol

To treat a severe form of Niemann-Pick disease type C

PAT

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

///////////adrabetadex, anax labs, APPROVALS 2026, FDA 2026, Lembaz, 8W6Q67R6NX, KLEPTOSE HPB, VT-270, VTS270, VTS-270, Niemann–Pick disease type C,

#adrabetadex, #anax labs, #APPROVALS 2026, #FDA 2026, #Lembaz, #8W6Q67R6NX, #KLEPTOSE HPB, #VT-270, #VTS270, #VTS-270, #Niemann–Pick disease type C,

Neladalkib


Giredestrant


Giredestrant

CAS 1953133-47-5

MF C27H31F5N4O MW 522.6 g/mol

3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol

Wilserdly, FDA 2026, APPROVALS 2026, GDC 9545, RG 6171, RO 7197597, 28P3DU6DB3

To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting

Giredestrant is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.

Giredestrant, sold under the brand name Wilserdly, is an oral selective estrogen receptor degrader (SERD) used for the treatment of estrogen receptor-positive (ER+) breast cancer.[1][2] It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency.[1][3] Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein.[1][4][5]

Research

In clinical trials, giredestrant has been evaluated in patients with ER+breast cancer , including those with ESR1 mutations, both as a single agent and in combination with other therapies.[2][6] Its orally bioavailable.[3][4]

SCHEME

PAT

WO2016097072 – TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

F HOFFMANN LA ROCHE – WO2016/97072, 2016, A1, https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016097072&_cid=P22-MWMY5D-43733-1

PAT

US20160175289 – Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

https://patentscope.wipo.int/search/en/detail.jsf?docId=US174233194&_cid=P22-MWMXSA-28614-1

SYN

compound 35 [PMID: 34251202]

Journal of Medicinal Chemistry, 2021, vol. 64, # 16, p. 11841 – 11856

SYN

https://www.sciencedirect.com/org/science/article/abs/pii/S1083616022002432

Organic Process Research & Development, Date: 18 March 2022, Pages: 568-582 Volume: Volume 26, Issue 3

GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2– breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C–N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet–Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.

PATENTS

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

Clinical data
Trade namesWilserdly
Other namesGDC-9545, RG6171, RO7197597
Identifiers
IUPAC name
CAS Number1953133-47-5
PubChem CID121410806
ChemSpider103748880
UNII28P3DU6DB3
KEGGD11961
ChEMBLChEMBL4650316
Chemical and physical data
FormulaC27H31F5N4O
Molar mass522.564 g·mol−1
3D model (JSmol)Interactive image
SMILES
InChI

References

  1. “Giredestrant (GDC-9545)”. Cancer.gov. U.S. National Cancer Institute. 14 November 2024.
  2. Malhi V, Agarwal P, Gates MR, Liu L, Wang J, De Bruyn T, et al. (December 2023). “Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer”. Cancer Research Communications. 3 (12): 2551–2559. doi:10.1158/2767-9764.CRC-23-0324. PMC 10722959. PMID 38019116.
  3. “A clinical study to compare giredestrant with fulvestrant, both combined with a targeted therapy (CDK4/6 inhibitor) in people with ER-positive, HER2-negative breast cancer that has come back after adjuvant hormone therapy”. Roche.
  4. Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, et al. (February 2024). “Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer”. Clinical Cancer Research. 30 (4): 754–766. doi:10.1158/1078-0432.CCR-23-1796. PMC 10870118. PMID 37921755.
  5. Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, et al. (August 2021). “GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer”. Journal of Medicinal Chemistry. 64 (16): 11841–11856. doi:10.1021/acs.jmedchem.1c00847. PMID 34251202.
  6. Lawrence L (25 July 2024). “Giredestrant Bests Anastrozole in ER+, HER2- Early Breast Cancer”.

Further reading

/////////////Giredestrant, ANAX LABS, GDC 9545, RG 6171, RO 7197597, Wilserdly, FDA 2026, APPROVALS 2026, GDC-9545, RG6171, RO7197597, 28P3DU6DB3, breast cancer

#Giredestrant, #ANAX LABS, #GDC 9545, #RG 6171, #RO 7197597, #Wilserdly, #FDA 2026, #APPROVALS 2026, #GDC-9545, #RG6171, #RO7197597, #28P3DU6DB3, #breast cancer

Vilzemetkib


PIMICOTINIB


Zamzetoclax


Zavolosotine


Zelenirstat


Zemirciclib


Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.7K other subscribers

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP